Total Revenue: $15.4B Founded Year: 1916 Total Employees: 29,900 Headquarters: Melbourne, Australia Market Cap: $47.64B Stock Exchange: ASX CSL is a global biotechnology company focused on developing and delivering plasma-derived therapies, vaccines, and specialty medicines, operating through key segments like CSL Behring, CSL Seqirus, and CSL Vifor collectively addressing rare diseases, immunology, and infectious diseases
Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
Sharing is caring Treatments tailored to you Weight loss can feel overwhelming
Understanding GLP-1 Basics Before Injection Before jumping into the injection process, its super important to understand how GLP-1 meds work and what to expect
In 2025, the company reported a +6.03% YoY revenue growth, supported by its key therapies: Darzalex ($14.35B) continues to lead in multiple myeloma with strong global demand, Stelara ($6.07B) remains a major contributor despite upcoming patent pressures, and Tremfya ($5.15B) is gaining traction in immunology with expanding use across indications
Fortunately, this is manageable
/product/02/3175523/2.jpg?6062)
